$BDSX

SCHULER JACK W purchased $367K of BDSX (indirect holdings)

SCHULER JACK W purchased 15,000 indirectly-held shares of BIODESIX INC (BDSX) at $24.47 ($0.37M total) on 2026-08-12.

Original reporting
SEC EDGAR · SCHULER JACK W
Published Aug 13, 2026, 9:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BDSX
Neutral
low confidence
Mentioned
$BDSX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDSXNeutralLow
01

Why it matters

The only new information is the disclosed open-market purchase size, price, and post-transaction share count; there is no operational or financial update in the text.

02

Market read

Traders may note the insider buy as a sentiment datapoint, but it does not provide a direct fundamental trigger.

03

What to watch

No 10b5-1 plan is stated, but the article provides no context on prior holdings, motivations, or whether other insiders acted.

Relevance 5/10Novelty 4/10Timing: filed 2026-08-13, transaction dated 2026-08-12

Background

This is an SEC Form 4 insider transaction disclosure for BioDeSix (BDSX) by a 10% owner, reported via indirect holdings.

Company-level read

Ticker impact

$BDSXNeutralLow confidence
Context

Schuler Jack W, a 10% owner, bought 15,000 shares of BioDeSix (BDSX) on 2026-08-12 at $24.4661.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider buys can be informative, but this is an indirect holding with no 10b5-1 plan and no accompanying operational news in the text.

Market effects

No sector-level implications are disclosed beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase may reflect routine liquidity or portfolio rebalancing rather than a new bullish thesis, especially given the indirect ownership form.

Key entities

  • BIODESIX INC

    Company whose shares were purchased; Form 4 insider transaction disclosed.

  • SCHULER JACK W

    10% owner who reported an indirect open-market purchase of 15,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BDSXMedAI 8/10

Biodesix (BDSX) Q2 2026 Earnings Call Transcript

Biodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.

$BDSXHigh

BIODESIX INC (BDSX): Results of Operations and Financial Condition

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere